BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31703842)

  • 1. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
    Chen F; Pei S; Wang X; Zhu Q; Gou S
    Biochem Biophys Res Commun; 2020 Jan; 521(3):753-761. PubMed ID: 31703842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.
    Wang X; Li L; Pei S; Zhu Q; Chen F
    Pharmazie; 2020 Mar; 75(2):94-101. PubMed ID: 32213241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F; Huang X; Wu M; Gou S; Hu W
    Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F; Qin X; Xu G; Gou S; Jin X
    Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability.
    Chen F; Xu G; Tian W; Gou S
    Biochem Pharmacol; 2021 Nov; 193():114785. PubMed ID: 34562469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
    Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug.
    Pathak RK; Dhar S
    Chemistry; 2016 Feb; 22(9):3029-36. PubMed ID: 26807548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
    Xu W; Chen Q; Wang Q; Sun Y; Wang S; Li A; Xu S; Røe OD; Wang M; Zhang R; Yang L; Zhou J
    Cell Death Dis; 2014 Dec; 5(12):e1551. PubMed ID: 25476899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z; Deng Z; Zhu G
    Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
    Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
    J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks.
    Wang S; Gong Z; Chen R; Liu Y; Li A; Li G; Zhou J
    Nucleic Acids Res; 2009 Apr; 37(6):1936-50. PubMed ID: 19208635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
    Wang M; Li G; Jiang G; Cai J; Liu Z; Huang R; Huang X; Wang H
    J Med Chem; 2024 Apr; 67(8):6218-6237. PubMed ID: 38573870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
    ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H; Wang X; Gou S
    J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum(IV) Prodrugs.
    Venkatesh V; Sadler PJ
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
    Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
    Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photoactivatable platinum complexes.
    Bednarski PJ; Mackay FS; Sadler PJ
    Anticancer Agents Med Chem; 2007 Jan; 7(1):75-93. PubMed ID: 17266506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
    Song XQ; Ma ZY; Wu YG; Dai ML; Wang DB; Xu JY; Liu Y
    Eur J Med Chem; 2019 Apr; 167():377-387. PubMed ID: 30784875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D
    Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance.
    Chen F; Xu G; Qin X; Jin X; Gou S
    J Pharmacol Exp Ther; 2017 Nov; 363(2):221-239. PubMed ID: 28916659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.